American Association for Cancer Research
Browse

Supplementary Table S1 from Reduced Platelet Activation in Triple-Negative Essential Thrombocythemia Compared with JAK2V617F-Mutated Essential Thrombocythemia

Download (114.66 kB)
journal contribution
posted on 2024-12-02, 08:20 authored by Huan Dong, Jia Chen, Jing Zhang, Feng Xue, Huiyuan Li, Donglei Zhang, Hu Zhou, Xian Zhang, Yueting Huang, Xiaofan Liu, Yunfei Chen, Wei Liu, Ying Chi, Wentian Wang, Ting Sun, Mankai Ju, Xinyue Dai, Wenjing Gu, Renchi Yang, Rongfeng Fu, Lei Zhang

Supplementary Table S1. Basic characteristics of ET patients and healthy donors.

Funding

National Science and Technology Major Project (国家科技重大专项)

National Natural Science Foundation of China (NSFC)

Clinical Research Fund of National Center for Clinical Medical Research for hematology Diseases

CAMS Innovation Fund for Medical Sciences

National Key Research and Development Program of China (NKPs)

History

ARTICLE ABSTRACT

Triple-negative (TN) essential thrombocytopenia (ET) is characterized by the absence of driver mutations while retaining histologic and phenotypic characteristics sufficient for an ET diagnosis. Our understanding of TN-ET and its platelet activation remains incomplete. We carried out a large-scale multicenter clinical analysis to analyze the clinical and molecular characteristics and thrombotic complications of TN-ET. We also related the above characteristics to platelet activation to further explore the thrombosis mechanism of TN-ET. A retrospective multicenter study was conducted on 138 patients with TN-ET and 759 patients with ET with driver mutations from March 1, 2012 to December 1, 2021. The clinical and molecular characteristics of the patients with TN-ET were summarized. Additionally, platelet activation, apoptosis, and reactive oxygen species (ROS) levels were analyzed in 73 patients with TN-ET from this cohort and compared with 41 age- and sex-matched healthy donors. Compared with patients with the JAK2V617F mutation, those with TN mutation were younger (P < 0.001) and exhibited fewer thrombotic events before diagnosis (P < 0.001) and during follow-up (P = 0.039). Patients with TN mutation also presented with significantly reduced CD62P expression in platelets (P = 0.031), slightly reduced calcium concentration in platelets (P = 0.063), increased mitochondrial membrane potential (P = 0.011), reduced phosphatidylserine exposure (P = 0.015), reduced levels of ROS (P = 0.043) and MitoSOX in platelets (P = 0.047). In comparison with JAK2V617F-mutated ET, TN-ET is associated with lower platelet ROS levels, which leads to reduced platelet activation and consequently a lower risk of thrombosis.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC